{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:13Z","timestamp":1792432033514,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Modulator therapy restores CFTR function and has led to health benefits for persons with cystic fibrosis (CF) (PwCF), including lower rates of pulmonary exacerbations. It is unknown if modulators affect lung function trajectories after inpatient treatment of pulmonary exacerbations (PEx).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective review of hospital encounters for PEx for subjects 6\u201325 years old with mild to moderate lung disease admitted to a large tertiary care center from 2014 to 2021 to capture hospitalizations of PwCF before and after starting modulators. Descriptive analyses were used to characterize the population and lung function findings. Logistic regression analyses were conducted to assess the association between modulators and FEV1pp outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study sample included 575 encounters representing 149 unique PwCF. Hospital encounters of PwCF taking modulator were associated with higher mean FEV1pp at baseline, midway, discharge, and follow-up assessments. Mean FEV1pp increased during inpatient treatment of PEx with loss of lung function at follow-up, regardless of modulator use. Hospital encounters of PwCF not taking modulators were associated with less significant improvements in mean FEV1pp from admission at both midway and discharge (15.6% vs. 18.3%, 19.9% vs. 22.5%, no modulator vs. modulator groups, respectively). At follow-up, hospitalizations of PwCF taking modulators were associated with a significantly higher probability of sustained improvement in FEV1pp from discharge (difference in probabilities 0.119, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05) and a lower probability of loss of lung function from baseline (difference in probabilities \u22120.123, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hospitalizations for PwCF taking modulators were associated with higher lung function at all assessments. Hospitalizations of PwCF taking modulators were associated with a significantly higher probability of sustained improvement in FEV1pp following discharge and a lower probability of loss of lung function from baseline.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1654122","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:34Z","timestamp":1755749434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of modulators on lung function following inpatient treatment for CF exacerbations"],"prefix":"10.3389","volume":"13","author":[{"given":"Anne","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith B.","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne A.","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Markwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin D.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1513\/AnnalsATS.201802-075FR","article-title":"Cystic fibrosis: translating molecular mechanisms into effective therapies","volume":"15","author":"Jennings","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1513\/AnnalsATS.202401-030RL","article-title":"Effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with mildly decreased and normal lung function: a real-life observational study","volume":"21","author":"Yaacoby-Bianu","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1165\/rcmb.2021-0359OC","article-title":"Cystic fibrosis airway mucus hyperconcentration produces a vicious cycle of mucin, pathogen, and inflammatory interactions that promotes disease persistence","volume":"67","author":"Batson","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.chest.2018.03.005","article-title":"Cystic fibrosis sputum rheology correlates with both acute and longitudinal changes in lung function","volume":"154","author":"Ma","year":"2018","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1164\/rccm.201001-0057OC","article-title":"Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes","volume":"182","author":"Collaco","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1465-9921-11-137","article-title":"Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations","volume":"11","author":"VanDevanter","year":"2010","journal-title":"Respir Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"key":"B17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jcf.2023.06.012","article-title":"Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis","volume":"22","author":"McElvaney","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1752-699X.2011.00246.x","article-title":"Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience","volume":"6","author":"Briggs","year":"2012","journal-title":"Clin Respir J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00408-018-0082-1","article-title":"Timing of spirometry may impact hospital length of stay for cystic fibrosis pulmonary exacerbation","volume":"196","author":"Krivchenia","year":"2018","journal-title":"Lung"},{"key":"B22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/1479972317743756","article-title":"Daily spirometry in an acute exacerbation of adult cystic fibrosis patients","volume":"15","author":"Stephen","year":"2018","journal-title":"Chron Respir Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/thoraxjnl-2014-206750","article-title":"Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis","volume":"71","author":"Heltshe","year":"2016","journal-title":"Thorax"},{"key":"B24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ppul.21117","article-title":"Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis","volume":"45","author":"Sanders","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway Bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ppul.25204","article-title":"Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations","volume":"56","author":"Muirhead","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcf.2020.10.003","article-title":"The global impact of SARS-CoV-2 in 181 people with cystic fibrosis","volume":"19","author":"McClenaghan","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2201519","DOI":"10.1183\/13993003.01519-2022","article-title":"European Respiratory Society\/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update","volume":"62","author":"Bhakta","year":"2023","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV(1) percent predicted among people with cystic fibrosis()","volume":"23","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A pilot randomized clinical trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","volume":"20","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1654122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:36Z","timestamp":1755749436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1654122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":34,"alternative-id":["10.3389\/fped.2025.1654122"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1654122","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1654122"}}